Three other genes were also down-regulated (SMARCA4, BAZ2A and SMARCC2): SMARCA4 is a drug target candidates in hyperdiploid multiple myeloma [50]; BAZ2A is a novel nucleolar chromatin remodeling machine [51], and SMARCC2 was among the top discriminating genes in the good prognosis subgroup of MLL [52]. The gene discussed is KMT2A; the disease is plasma cell myeloma.